Impact of Comorbidities and Severity on Outcomes in Bronchiectasis Excerbations

NCT07346625 | Not Yet Recruiting

• 1 other identifier: Soh-Med-25-9-16MS
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Acute exacerbations of bronchiectasis are associated with variable outcomes depending on patient factors. Comorbidities such as COPD, diabetes, and cardiovascular disease, as well as disease severity scores, significantly influence hospitalization rates, length of stay, need for intensive care, and mortality. Understanding these associations helps in risk stratification, guiding management, and improving prognosis in affected patients.

Conditions

Bronchiectasis With Acute Exacerbation

Outcome Measures

Primary Outcomes (1)

• Composite Clinical treatment failure during Bronchiectasis Exacerbation

  composite clinical treatment failure,defined as the occurrence of any of the following events within 30 days of bronchiectasis exacerbation onset: 1.hospitalization related to the exacerbation 2.escalation or change of antibiotic therapy 3.Admission to the intensive care unit 4.Death from any cause

  30 days after exacerbation onset

Secondary Outcomes (1)

• correlation between disease severity and clinical treatment failure

  1 year

Study Arms (1)

adult bronchiectasis patient with acute excerbations

Group 1: Mild-to-Moderate Disease Severity Patients diagnosed with bronchiectasis who present with acute exacerbations and have mild to moderate disease severity scores (based on BSI or FACED scoring). Data on comorbidities, clinical outcomes, and hospital stay will be recorded. Group 2: Severe Disease Severity Patients with acute exacerbations of bronchiectasis classified as severe according to BSI or FACED score. These patients are expected to have higher comorbidity burden and worse clinical outcomes. Alternative grouping (if by comorbidity burden): Group A: With Significant Comorbidities Patients with one or more major comorbidities such as COPD, diabetes, or cardiovascular disease. Group B: Without Significant Comorbidities Patients without major comorbid conditions, serving as a comparison group.

Other: Observational assessment of comorbidities and disease severity

Interventions

Observational assessment of comorbidities and disease severity OTHER

\> This study involves no active intervention. Data will be collected from patients with acute exacerbations of bronchiectasis to assess the impact of comorbidities and disease severity on clinical outcomes such as hospital stay, ICU admission, and mortality.

adult bronchiectasis patient with acute excerbations

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will include adult patients (≥18 years) diagnosed with bronchiectasis who are admitted to the hospital with acute exacerbations. Patients will be recruited from the Department of Chest Diseases at Sohag University Hospital (or your hospital name). All eligible patients during the study period will be included consecutively. Data regarding demographic characteristics, comorbidities, disease severity scores (BSI or FACED), and clinical outcomes will be collected and analyzed.

You may qualify if:

• Adults (≥18 years) admitted with a diagnosis of "Bronchiectasis with acute exacerbation". The bronchiectasis exacerbation is diagnosed based on deterioration in three or more of the following main symptoms for 48h at least: cough, sputum volume or sputum consistency, purulent sputum, breathlessness or exercise tolerance, fatigue or malaise, hemoptysis, and the requirement of a change in the bronchiectasis treatment as determined by a clinician.

You may not qualify if:

• Patients younger than 18 years of age. Patients who refuse participation or whose medical records lack informed consent (if applicable).

Sponsors & Collaborators

• Sohag University: lead

MeSH Terms

Interventions

Patient Acuity

Intervention Hierarchy (Ancestors)

Health Status Indicators; Health Surveys; Surveys and Questionnaires; Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Impact of comorbiditries and Disease severity on clinical outcomes of patients with acute exacerbations of bronchiectesis

Study Record Dates

• First Submitted: November 16, 2025
• First Posted: January 16, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: January 16, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share